Skip to main content
Signal8
Launch Terminal

ILLUMINA, INC. (ILMN)

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

Sector: Laboratory Analytical Instruments

Industry: Medical - Diagnostics & Research

Illumina, Inc. logo

Illumina, Inc.

NASDAQ:ILMNHealthcare
-18.64%$235.99
AH$236.54+0.23%vs close
Mkt Cap$35.68B
Float142.79M
O/S151.2M
Vol
$ Vol
RVOL
Inst Own-
SI5.5%
Earnings
Dilution
Illumina, Inc. logoNASDAQ:ILMN$235.99-18.64%
Phase Distribution
12 lead-sponsored trials·0 active·10 completed
Not applicable12
(14 more as collaborator)
Status Overview
Completed10
Unknown2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
  • Observational
    Completed

    Detection of Factor V Leiden G1691A and Factor II (Prothrombin) G20210A Point Mutations in DNA

    -

    Detection and Genotyping of Factor V and Factor II Point Mutations

    Enrollment
    275
    Start
    Aug 2009
    Primary Completion
    Sep 2009
    Completion
    Sep 2009
    NCT00959504
  • Observational
    Completed

    Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality Test

    -

    Post-natal Cytogenetics

    Enrollment
    900
    Start
    Aug 2011
    Primary Completion
    Nov 2011
    Completion
    Nov 2011
    NCT01426308
  • Not applicable
    Completed

    Single Embryo TrAnsfeR of Euploid Embryo

    Preimplantation Genetic Screening by NGS

    Infertility, Aneuploidy

    Enrollment
    661
    Start
    Sep 2014
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02268786
  • Observational
    Completed

    Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers

    -

    Preeclampsia

    Enrollment
    242
    Start
    Mar 2016
    Primary Completion
    Nov 2017
    Completion
    Nov 2017
    NCT02808494
  • Not applicable
    Completed

    NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants

    clinical whole genome sequencing (cWGS)

    Rare Diseases

    Enrollment
    355
    Start
    Sep 2017
    Primary Completion
    Apr 2019
    Completion
    Jan 2020
    NCT03290469
  • Observational
    Completed

    Collection of Whole Blood Specimens in Pregnant Women

    -

    Pregnancy Related

    Enrollment
    3,000
    Start
    Feb 2017
    Primary Completion
    Aug 2019
    Completion
    Dec 2019
    NCT03590678
  • Observational
    Completed

    A Study Collecting Blood Samples From Pregnant Women to Aid in the Development of a Noninvasive Prenatal Test

    -

    Pregnancy

    Enrollment
    2,209
    Start
    May 2018
    Primary Completion
    Dec 2019
    Completion
    Dec 2019
    NCT03620110
  • Observational
    Completed

    NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult Neurology

    clinical Whole Genome Sequencing

    Neurologic Deficits, Neurologic Disorder +1

    Enrollment
    160
    Start
    Nov 2019
    Primary Completion
    Jan 2024
    Completion
    Jan 2024
    NCT04170985
  • Observational
    Completed

    Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina Personnel

    COVIDSeq Test

    SARS-CoV-2

    Enrollment
    763
    Start
    Feb 2020
    Primary Completion
    Feb 2021
    Completion
    Feb 2021
    NCT04561089
  • Observational
    Completed

    Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population

    Diagnostic test for detection of SARS-CoV-2

    SARS-CoV-2

    Enrollment
    644
    Start
    Sep 2020
    Primary Completion
    Feb 2021
    Completion
    Feb 2021
    NCT04561102
  • Observational
    Unknown status

    iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, Early Onset Disorders

    -

    Genetic Disease

    Enrollment
    150
    Start
    Nov 2021
    Primary Completion
    Dec 2021
    Completion
    Dec 2024est.
    NCT05049967
  • Not applicable
    Unknown status

    CardioSeq: Impact of WGS in Individuals With CVD

    TruGenome Cardiovascular Disease test

    Cardiovascular Diseases

    Enrollment
    1,500
    Start
    Jan 2023
    Primary Completion
    Dec 2024est.
    Completion
    Jun 2025est.
    NCT05656183
Search ClinicalTrials.gov for “Illumina”